Allogene Historical Cash Flow
| ALLO Stock | USD 1.89 0.18 8.70% |
Analysis of Allogene Therapeutics cash flow over time is an excellent tool to project Allogene Therapeutics future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Change In Cash of 21.4 M or Net Borrowings of 93.5 M as it is a great indicator of Allogene Therapeutics ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Allogene Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Allogene Therapeutics is a good buy for the upcoming year.
Allogene |
About Allogene Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Allogene balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Allogene's non-liquid assets can be easily converted into cash.
Allogene Therapeutics Cash Flow Chart
Add Fundamental
Capital Expenditures
Capital Expenditures are funds used by Allogene Therapeutics to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Allogene Therapeutics operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Free Cash Flow
The amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.Most accounts from Allogene Therapeutics' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Allogene Therapeutics current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Allogene Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. To learn how to invest in Allogene Stock, please use our How to Invest in Allogene Therapeutics guide.At this time, Allogene Therapeutics' End Period Cash Flow is very stable compared to the past year. As of the 18th of December 2024, Other Cashflows From Investing Activities is likely to grow to about 134.5 M, while Depreciation is likely to drop about 8.5 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Capital Expenditures | 21.4M | 5.2M | 1.5M | 1.4M | Depreciation | 10.5M | 14.3M | 14.2M | 8.5M |
Allogene Therapeutics cash flow statement Correlations
Click cells to compare fundamentals
Allogene Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Allogene Therapeutics cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Investments | 214.9M | (439.2M) | 185.1M | 106.2M | 145.4M | 152.7M | |
| Change In Cash | 85.7M | 13.4M | (9.2M) | (111.4M) | 21.3M | 21.4M | |
| Total Cashflows From Investing Activities | 164.1M | (505.1M) | 163.7M | 106.2M | 122.1M | 128.2M | |
| Depreciation | 5.0M | 7.6M | 10.5M | 14.3M | 14.2M | 8.5M | |
| Capital Expenditures | 50.8M | 66.0M | 21.4M | 5.2M | 1.5M | 1.4M | |
| Total Cash From Operating Activities | (137.4M) | (115.1M) | (184.8M) | (220.5M) | (237.7M) | (225.8M) | |
| Change To Operating Activities | (5.9M) | 14.3M | 7.2M | (1.6M) | (1.9M) | (1.8M) | |
| Net Income | (184.6M) | (250.2M) | (257.0M) | (332.6M) | (327.3M) | (343.6M) | |
| Total Cash From Financing Activities | 59.0M | 633.6M | 12.0M | 3.0M | 95.7M | 90.9M | |
| Change To Netincome | 52.5M | 69.2M | 80.8M | 94.1M | 84.7M | 76.9M | |
| Change To Liabilities | 2.9M | 18.1M | 3.9M | 5.3M | 4.8M | 6.8M | |
| Sale Purchase Of Stock | 1.8M | 2.8M | 3.6M | 2.5M | 2.2M | 2.1M | |
| Stock Based Compensation | 46.1M | 65.3M | 80.8M | 83.6M | 66.0M | 66.0M | |
| Free Cash Flow | (188.1M) | (181.1M) | (206.3M) | (225.7M) | (239.2M) | (251.2M) | |
| Change In Working Capital | (6.9M) | 53.9M | (32.1M) | 3.7M | (15.3M) | (14.5M) | |
| Begin Period Cash Flow | 93.7M | 179.4M | 192.8M | 183.6M | 72.2M | 132.3M | |
| Other Cashflows From Financing Activities | 59.0M | 11.7M | 12.0M | 3.0M | 4.6M | 4.4M | |
| Other Non Cash Items | 3.4M | 4.0M | 2.6M | 2.4M | 24.7M | 22.9M | |
| Issuance Of Capital Stock | 54.2M | 621.9M | 11.4M | 87.9M | 91.1M | 86.6M | |
| End Period Cash Flow | 179.4M | 192.8M | 183.6M | 72.2M | 93.4M | 108.7M | |
| Other Cashflows From Investing Activities | 214.9M | (439.2M) | 185.1M | 111.4M | 128.1M | 134.5M |
Pair Trading with Allogene Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Allogene Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Allogene Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Allogene Stock
Moving against Allogene Stock
| 0.66 | DYAI | Dyadic International | PairCorr |
| 0.52 | ESPR | Esperion Therapeutics Buyout Trend | PairCorr |
| 0.51 | BMY | Bristol Myers Squibb | PairCorr |
The ability to find closely correlated positions to Allogene Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Allogene Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Allogene Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Allogene Therapeutics to buy it.
The correlation of Allogene Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Allogene Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Allogene Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Allogene Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Allogene Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. To learn how to invest in Allogene Stock, please use our How to Invest in Allogene Therapeutics guide.You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Allogene Therapeutics. If investors know Allogene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Allogene Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.55) | Quarterly Revenue Growth (0.27) | Return On Assets (0.26) | Return On Equity (0.54) |
The market value of Allogene Therapeutics is measured differently than its book value, which is the value of Allogene that is recorded on the company's balance sheet. Investors also form their own opinion of Allogene Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Allogene Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Allogene Therapeutics' market value can be influenced by many factors that don't directly affect Allogene Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Allogene Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Allogene Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Allogene Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.